Learn More
BACKGROUND There have been concerns about the cardiovascular safety of omalizumab. OBJECTIVES In this study, the clinical status of the omalizumab receiving severe asthma patients and the cytokine(More)
BACKGROUND The changes and correlations of TRAIL (TNF-related apoptosis-inducing-ligand) and CXCL8 (IL8) prior to treatment and three months following therapy as well as the corresponding Positron(More)